MAIA Biotechnology opens second US site for THIO-101 trial

MAIA Biotechnology has opened enrolment at a second clinical site in the US for its THIO-101 Phase II expansion trial, evaluating ateganosine for the treatment of NSCLC. The trial is active in Europe and Asia across 44 sites in six countries and now includes two in the US. Ateganosine is a first-in-class investigational telomere-targeting agent under evaluation for activity against NSCLC. Credit: Saiful52 / Shutterstock.com. MAIA Biotechnology has opened enrolment at a second clinical site in the US for its THIO-101 Phase II expansion trial, evaluating ateganosine for the treatment of non-small cell lung cancer (NSCLC). The trial at Central…

Source: Clinical Trials Arena